中科微点-全球专利检索

  1. Login
  2. Sign Up
Invention Grant
US09447063B2 Disubstituted adamantyl derivative or pharmaceutically acceptable salt thereof, production method for same, and pharmaceutical composition for suppressing cancer metastasis comprising same as active ingredient 有权
二取代金刚烷基衍生物或其药学上可接受的盐，其制备方法和用于抑制癌转移的药物组合物，其包含与活性成分

Disubstituted adamantyl derivative or pharmaceutically acceptable salt thereof, production method for same, and pharmaceutical composition for suppressing cancer metastasis comprising same as active ingredient
Abstract:
The present invention relates to a novel disubstituted adamantyl derivative or the pharmaceutically acceptable salts thereof, a method for preparing the same, and a pharmaceutical anticancer or antimetastasis composition comprising the same as an active ingredient. The disubstituted adamantyl derivative of the present invention suppressed accumulation of HIF-1α, inhibiting the expression of the metastasis related protein Twist dose-dependently. Thus, the disubstituted adamantyl derivative of the invention is effective in inhibiting the expressions of the metastasis related proteins, β-catenin and RohA, and the EMT related genes such as MMP2 and MMP9, without cytotoxicity. Therefore, the disubstituted adamantyl derivative or the pharmaceutically acceptable salts thereof of the invention can be efficiently used as a pharmaceutical anticancer or antimetastasis composition.
Abstract(Chinese):

本发明涉及新的二取代金刚烷基衍生物或其药学上可接受的盐，其制备方法，以及含有该活性成分的药物抗癌或抗转移组合物。 本发明的二取代金刚烷基衍生物抑制HIF-1α的积累，抑制转移相关蛋白的表达量呈剂量依赖性。 因此，本发明的二取代金刚烷基衍生物可有效抑制转移相关蛋白，β-连环蛋白和RohA以及EMT相关基因如MMP2和MMP9的表达，无细胞毒性。 因此，本发明的二取代金刚烷基衍生物或其药学上可接受的盐可以有效地用作药物抗癌或抗转移组合物。

Public/Granted literature
Information query
Espacenet
Patent Agency Ranking
0/0